INDUSTRY × Breast Neoplasms × Dermatologic × Clear all
NCT05461430 2026-04-13

TraveraRTGx

Travera Inc

Completed
72 enrolled
NCT02568267 2026-03-06

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 2 FDA
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
NCT06242470 2026-02-05

A Study of MGC026 in Participants With Advanced Solid Tumors

MacroGenics

Phase 1 Recruiting
250 enrolled
NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Second Life Therapeutics

Phase 1/2 Not yet recruiting
60 enrolled
NCT06022029 2025-12-24

ON-5001

OncoNano Medicine, Inc.

Phase 1 Recruiting
168 enrolled
NCT03452774 2025-10-28

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio, Inc.

Recruiting
50,000 enrolled
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

Phase 1/2 Active not recruiting
98 enrolled
NCT04140526 2025-05-23

PRESERVE-001

OncoC4, Inc.

Phase 1/2 Active not recruiting
733 enrolled
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
NCT05500508 2024-12-24

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Aminex Therapeutics, Inc.

Phase 1/2 Terminated
15 enrolled
NCT04028479 2024-12-18

ROOT

Taproot Health

Completed
167 enrolled
NCT06583395 2024-11-01

QUANTUM

VitaMed Research LLC

Enrolling by invitation
3,000 enrolled
NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 1/2 Active not recruiting
179 enrolled
NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
NCT01931644 2024-04-18

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Sanguine Biosciences

Completed
17,667 enrolled
NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Unknown
71 enrolled
NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled